Section: NEW AND EMERGING
BIOMARKERS AND DRUG TARGETS
Organizing Secretary: Stephen T. Furlong
Director, Discovery Medicine
AstraZeneca Pharmaceuticals, USA
PLENARY LECTURES
|
The Challenges of Implementing Biomarkers in
Clinical Trials
Stephen T. Furlong
Director, Discovery Medicine, AstraZeneca Pharmaceuticals,
USA
|
| INVITED LECTURES
|
Development and Validation of Emerging “Omic”
Biomarkers for New Drugs: An Overview of Lessons Learned
from High Technology Materials
Bruce A. Fowler
Division of Toxicology and Environmental Medicine,
Agency for Toxic Substances and Disease Registry, USA
|
| Cheminformatics Delivers Super-Antibiotics
for Superbugs
A.R. Cherkasov
Division of Infectious Diseases, Faculty of Medicine,
University of British Columbia, USA
|
|
